FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

  • NWOW
    Categories: ,

    New Ways of Working in a new era: EORTC new hybrid work model based on collaboration and flexibility

    Categories: ,

    RECIST disease assessment is effective for targeted treatment as well as classical chemotherapy

  • men-on-bench

    EORTC trial to improve treatment for older patients with acute myeloid leukemia enrolls first patients

  • a-negrouk
    Categories: ,

    EORTC’s Anastassia Negrouk speaks out on the EU Data Protection Regulation

  • Statue

    Male and female breast cancers are not identical

  • New Data at ASH 2014 Highlight Progress of Pfizer’s Growing Portfolio in Blood Cancers

  • EORTC to study cancer diagnostic/treatment approaches in nursing homes with the support of Armonea